BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26471485)

  • 21. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
    Zinzani PL; Pellegrini C; Broccoli A; Casadei B; Argnani L; Pileri S
    Am J Hematol; 2013 Nov; 88(11):E273-6. PubMed ID: 23843267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Follicular lymphoma showing long-term false positive results by FDG-PET after rituximab-containing chemotherapy].
    Miyazaki Y; Nawa Y; Kohashi S; Nakase K; Miyagawa M; Hara M
    Rinsho Ketsueki; 2012 Feb; 53(2):252-4. PubMed ID: 22450588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients].
    Oriuchi N; Higuchi T; Endo K; Tsukamoto N; Matsuda H; Kuji I; Murakami K; Nakajima K
    Kaku Igaku; 2009 Jun; 46(2):96-9. PubMed ID: 19637820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.
    Trotman J; Fournier M; Lamy T; Seymour JF; Sonet A; Janikova A; Shpilberg O; Gyan E; Tilly H; Estell J; Forsyth C; Decaudin D; Fabiani B; Gabarre J; Salles B; Van Den Neste E; Canioni D; Garin E; Fulham M; Vander Borght T; Salles G
    J Clin Oncol; 2011 Aug; 29(23):3194-200. PubMed ID: 21747087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.
    Rossi G; Marcheselli L; Dondi A; Bottelli C; Tucci A; Luminari S; Arcaini L; Merli M; Pulsoni A; Boccomini C; Puccini B; Micheletti M; Martinelli G; Rossi A; Zilioli VR; Bozzoli V; Balzarotti M; Bolis S; Cabras MG; Federico M
    Am J Hematol; 2015 Jan; 90(1):56-61. PubMed ID: 25327841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.
    Sacchi S; Pozzi S; Marcheselli L; Bari A; Luminari S; Angrilli F; Merli F; Vallisa D; Baldini L; Brugiatelli M;
    Cancer; 2007 May; 109(10):2077-82. PubMed ID: 17394190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging in follicular NHL.
    Hofman MS; Hicks RJ
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):165-77. PubMed ID: 21658616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
    Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
    J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of [18F]fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma.
    Baudard M; Comte F; Conge AM; Mariano-Goulart D; Klein B; Rossi JF
    Leuk Lymphoma; 2007 Feb; 48(2):381-8. PubMed ID: 17325900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
    Rossi D; Bruscaggin A; La Cava P; Galimberti S; Ciabatti E; Luminari S; Rigacci L; Tucci A; Pulsoni A; Bertoldero G; Vallisa D; Rusconi C; Spina M; Arcaini L; Angrilli F; Stelitano C; Merli F; Gaidano G; Federico M; Palumbo GA
    Haematologica; 2015 Apr; 100(4):517-24. PubMed ID: 25596266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study.
    Cottereau AS; Versari A; Luminari S; Dupuis J; Chartier L; Casasnovas RO; Berriolo-Riedinger A; Menga M; Haioun C; Tilly H; Tarantino V; Federico M; Salles G; Trotman J; Meignan M
    Blood; 2018 May; 131(22):2449-2453. PubMed ID: 29559480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging follicular lymphoma using positron emission tomography with [(18)F]fluorodeoxyglucose: to what purpose?
    Barrington SF; Mikhaeel NG
    J Clin Oncol; 2012 Dec; 30(35):4285-7. PubMed ID: 23109690
    [No Abstract]   [Full Text] [Related]  

  • 33. Prognostic significance of molecular remission in follicular lymphoma.
    Dührsen U; Hüttmann A; Dürig J
    J Clin Oncol; 2010 Oct; 28(30):e613; author reply e614. PubMed ID: 20713852
    [No Abstract]   [Full Text] [Related]  

  • 34. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Nomoto J; Miyamoto K; Fukuhara S; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
    Hum Pathol; 2013 Nov; 44(11):2529-35. PubMed ID: 23916290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progressive eyelid and facial swelling due to follicular lymphoma.
    Smith LB; Pynnonen MA; Flint A; Adams JL; Elner VM
    Arch Ophthalmol; 2009 Aug; 127(8):1068-70. PubMed ID: 19667354
    [No Abstract]   [Full Text] [Related]  

  • 36. The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma.
    Lu Z; Lin M; Downe P; Chong S; Ling S
    Ann Nucl Med; 2014 Oct; 28(8):805-11. PubMed ID: 25008291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Importance of Bone Marrow Uptake on Baseline
    Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
    Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
    Moskowitz CH; Schöder H; Teruya-Feldstein J; Sima C; Iasonos A; Portlock CS; Straus D; Noy A; Palomba ML; O'Connor OA; Horwitz S; Weaver SA; Meikle JL; Filippa DA; Caravelli JF; Hamlin PA; Zelenetz AD
    J Clin Oncol; 2010 Apr; 28(11):1896-903. PubMed ID: 20212248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.
    Martelli M; Ceriani L; Zucca E; Zinzani PL; Ferreri AJ; Vitolo U; Stelitano C; Brusamolino E; Cabras MG; Rigacci L; Balzarotti M; Salvi F; Montoto S; Lopez-Guillermo A; Finolezzi E; Pileri SA; Davies A; Cavalli F; Giovanella L; Johnson PW
    J Clin Oncol; 2014 Jun; 32(17):1769-75. PubMed ID: 24799481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy.
    Filippi AR; Piva C; Giunta F; Bellò M; Chiappella A; Caracciolo D; Zotta M; Douroukas A; Ragona R; Vitolo U; Bisi G; Ricardi U
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):311-6. PubMed ID: 23916170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.